UnitedHealth Group's pharmacy benefits manager, OptumRx Inc., was hit with an Employee Retirement Income Security Act of 1974 ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

Zepbound (tirzepatide) is a brand-name drug prescribed for weight loss, obstructive sleep apnea (OSA), and other uses in certain adults. Keep reading to learn more about getting Zepbound covered ...

Trizepatide (Zepbound), on the other hand, mimics two different hormones — GLP-1 and GIP — both of which the body produces after one eats. GIP bolsters how the body processes sugar and fat.

"Both Wegovy and Zepbound have demonstrated clinically significant weight reduction." "For example, if a patient has fatty liver, we will choose the GLP-1 that is proven to work best for liver ...

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S. pharmacy claims.

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

Why you should care: People taking Zepbound, Eli Lilly’s obesity drug, lost almost 50% more weight than individuals using Novo Nordisk’s Wegovy. According to a study funded by Eli Lilly, the ...

Drug companies offer discounts Both Zepbound-maker Eli Lilly and Wegovy-maker Novo Nordisk have discounted the price of their weight-loss medications for people who pay out of pocket. Novo Nordisk ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines.

Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy Zepbound achieved average weight reduction of 20.2% compared to 13.7% with Wegovy, according to a study funded by Lilly ...